Verastem, Inc., (NASDAQ: VSTM) a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells, announced the presentation of preclinical data at the American Society of Clinical Oncology Annual Meeting being held June 1 through June 5, 2012, in Chicago, IL. Verastem will present data on novel biomarkers that may enable improved discrimination of cancer stem cells from other cancer cells and normal tissue. Verastem will describe the use of multiple methodologies, including RNA signatures and alternative splicing biomarkers, to detect cancer stem cells. These biomarkers identified Triple Negative Breast Cancer tumors that were likely to recur following standard chemotherapy. Resistance to standard treatment is one of the defining characteristics of cancer stem cells. Verastem is developing diagnostics to identify patients whose tumors have a high percentage of cancer stem cells. These diagnostics may also be used to monitor a patient’s response to treatment. The schedule for the Verastem poster presentation is as follows: Date & Time: Saturday June 2, 8:00 AM to 12:00 PM (CDT) Poster Title: Use of gene expression and alternative splicing signatures to discriminate breast cancer stem cells from fibroblasts Abstract Number: 1057 Location: McCormick Place South (Hall A2) Session: Breast Cancer - Triple-negative/Cytotoxics/Local Therapy About Verastem, Inc. Verastem, Inc. (NASDAQ: VSTM) is a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is translating discoveries in cancer stem cell research into new medicines for the treatment of major cancers such as breast cancer. For more information please visit www.verastem.com. Forward-looking statements: Any statements in this press release about our strategy, future operations, future financial position, future expectations and plans and prospects for the Company, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include statements about the identification of potential biomarkers for use in patient selection and evaluation of therapeutic response. Actual results may differ materially from those indicated by such forward-looking statements as result of various important factors, including the unproven nature of our approach to the discovery and development of product candidates that target cancer stem cells, our reliance on our proprietary compound screening technology for drug discovery, our strategy to acquire or in-license additional compounds and product candidates and the uncertainties inherent in preclinical testing and clinical trials, among other factors discussed in the “Risk Factors” section of the Company's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2012, which is on file with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company’s views only as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.